PEGylation of conjugated linoleic acid and its application as an anti-cancer prodrug

Ji Hye Seo, Hyun-Seuk Moon, Ding Ding Guo, Hong Goo Lee, Yun Jaie Choi, Ng Su Cho

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The objective of this study is to investigate whether the PEGylated conjugated linoleic acid (PCLA) as an anti-cancer prodrug can have favorable stability, biological activity, and prevention of proliferation in MCF-7 breast cancer cells for anti-cancer when compared with conjugated linoleic acid (CLA) itself. The CLA was simply coupled to poly(ethylene glycol) (PEG) at melting state without solvent or catalyst through ester linkage between carboxylic group of CLA and hydroxyl one of PEG. The results showed that the half life of PCLA was 55h in cell culture medium at pH 7.4 and 37°C. Apoptosis of MCF-7 breast cancer cells were induced by not only CLA- but PCLA-treatment with increasing concentrations whereas PCLA increased cell viability when compared with CLA itself. These results indicate that the PCLA is a more stable and valuable prodrug in that it has good stability and inhibition of cancer cell proliferation.

Original languageEnglish
Pages (from-to)441-444
Number of pages4
JournalKey Engineering Materials
Volume342-343
Publication statusPublished - 2007 Apr 16
Externally publishedYes

Keywords

  • Anti-proliferation
  • Apoptosis
  • Conjugated linoleic acid
  • MCF-7 breast cancer cell
  • Pegylation
  • Poly(ethylene glycol)

ASJC Scopus subject areas

  • Ceramics and Composites
  • Chemical Engineering (miscellaneous)

Fingerprint Dive into the research topics of 'PEGylation of conjugated linoleic acid and its application as an anti-cancer prodrug'. Together they form a unique fingerprint.

  • Cite this

    Seo, J. H., Moon, H-S., Guo, D. D., Lee, H. G., Choi, Y. J., & Cho, N. S. (2007). PEGylation of conjugated linoleic acid and its application as an anti-cancer prodrug. Key Engineering Materials, 342-343, 441-444.